Neurotrope | IR
21675
page-template,page-template-full_width,page-template-full_width-php,page,page-id-21675,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Investors & Media

STOCK INFORMATION

Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

NASDAQ: NTRP

July 18, 2018 7:59 PM UTC
Copyright Nasdaq. Minimum 15 minutes delayed.

 

Click Refresh to update.  Market summary here.

10.55 -0.45 -4.09%

ANALYSTS

FirmAnalystPhone
Roth CapitalRobert Leboyer(646)-616-2785
Maxim GroupCaroline Palomeque(212)-895-3726

PRESS RELEASES

Press Release

NEW YORK, July 16, 2018 /PRNewswire/ — Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), is announcing that the first patient has been enrolled into its confirmatory Phase 2 clinical trial with its lead Alzheimer’s disease drug, Bryostatin-1.  Patient...

Read More
Press Release

NEW YORK, July 11, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), is announcing that it has established its Scientific Advisory Board (SAB) comprised of experts in the fields of AD and other...

Read More
Press Release

NEW YORK, July 2, 2018 /PRNewswire/ — Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), is announcing  the acceptance of a presentation at the Alzheimer’s Association International Conference 2018 (AAIC) being held in Chicago, from July 22-26,...

Read More
Press Release

NEW YORK, May 7, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary (the “Company”), has completed the study design for its confirmatory Phase 2 clinical...

Read More
Press Release

NEW YORK, Feb. 7, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the BIO CEO & Investor Conference to be...

Read More
Press Release

NEW YORK, Jan. 25, 2018 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that Dr. Daniel Alkon, President and CSO, will provide a corporate overview at the NobleCon 14th Annual Institutional Investor Conference to be...

Read More
Press Release

  NEW YORK, Jan. 5, 2018 /PRNewswire/ — Neurotrope (NTRP) today announced that a post-hoc analysis of data from its Phase 2 trial in patients with advanced Alzheimer’s disease (AD) found evidence of improvement in cognition in patients receiving the 20μg bryostatin regimen who did...

Read More
Press Release

  New York – December 18, 2017 – Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced the appointment of Charles S. Ryan, JD, PhD as Chief Executive Officer and Director. The appointment follows...

Read More
Press Release

NEW YORK, Dec. 19, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that it will present additional clinical findings from its Phase 2 bryostatin trial in patients with advanced AD in a keynote...

Read More
Press Release

    NEW YORK – August 9, 2017 – Neurotrope, Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today provided a business update outlining recent clinical development progress and financial results for the quarter ended June...

Read More
Press Release

NEW YORK, July 19, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP) today presented clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer’s disease (AD) patients treated with 20 µg bryostatin-1 showed preliminary evidence of sustained improvement in cognition compared to placebo. The...

Read More
Press Release

The presentation will be given by Dr. Martin R. Farlow, MD, Vice-Chairman for Research in the Department of Neurology, Indiana University School of Medicine, Indiana Alzheimer Disease Center. It will feature results from Neurotrope’s recently completed Phase 2 study of bryostatin – a protein kinase...

Read More
Press Release

 Data indicate that Bryostatin-1 improves cognition and the ability to perform activities of daily living Conference Call to Be Held Today, May 1, 2017, at 8:30 a.m. Eastern Time   NEW YORK, May 1, 2017 /PRNewswire/ — Neurotrope, Inc. (NASDAQ: NTRP) today announced positive top-line...

Read More
Press Release

Begins Trading on the NASDAQ Capital Market on March 29, 2017. Neurotrope Will Ring the Opening Bell on March 31, 2017   NEW YORK, March 27, 2017 PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s...

Read More
Press Release

Dr. Alkon to Discuss Neurotrope’s Regenerative Approach to Alzheimer’s Disease and Other Neurological Diseases by Turning on the Brain’s Endogenous Ability to Increase Synapses   NEW YORK, March 24, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative...

Read More
Press Release

  NEW YORK, March 16, 2017  PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer’s disease, today announced that it is scheduled to present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017...

Read More
Press Release

  Top-line efficacy data is expected to be announced in April 2017     NEW YORK, February 28, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced the conclusion of dosing and patient...

Read More
Press Release

    NEW YORK, February 7, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), announces that Susanne Wilke PhD, Neurotrope’s Chief Executive Officer, and Dr. Daniel Alkon, Neurotrope’s President and...

Read More
Press Release

Creates potential for an economical and commercially viable supply of Bryostatin-1     NEW YORK, Jan 30, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that it has signed a licensing...

Read More
Press Release

  NEW YORK, Jan 27, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital...

Read More
Press Release

      NEW YORK, January 12, 2017, /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that its Board of Directors has approved a 1-for-32 reverse stock split of the Company’s issued...

Read More
Press Release

  NEW YORK, January 5, 2017 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, announced today that Dr. Susanne Wilke, Ph.D., Neurotrope’s Chief Executive Officer, will be presenting a corporate overview at two investor...

Read More
Press Release

    NEW YORK, November 23, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today issued a statement on Eli Lilly’s experimental drug solanezumab.  Lilly stated that, based upon results from its recent Phase 3 clinical...

Read More
Press Release

  Top line Phase 2 study results expected to be released in April 2017   The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million   NEW YORK, November 22, 2016 /PRNewswire/ —...

Read More
Press Release

  Funding to complete Phase 2 trial in Alzheimer’s with top line results expected April 2017 Initiate clinical trial for Fragile X indication which has Orphan Drug Status File Application with the Nasdaq Capital Market     New York, NY. November 18, 2016  Neurotrope, Inc. (OTCQB:NTRP),...

Read More
Press Release

New York, NY, September 28, 2016 — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today announced that it has appointed its Chief Scientific Officer, Dr. Daniel Alkon, to the additional role of President.   After approximately...

Read More
Press Release

  NEWARK, N.J., September 6, 2016  — Neurotrope, Inc. (OTCQB:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer’s disease, today announced that it has appointed Dr. Susanne Wilke, PhD as Chief Executive Officer.  Dr. Wilke brings significant leadership, sector and investing...

Read More
Press Release

  NEW YORK, N.Y., August 15, 2016 (GLOBE NEWSWIRE) — Neurotrope, Inc. (OTCBB:NTRP) today announced that its wholly owned subsidiary, Neurotrope BioScience, Inc., has submitted to the Food and Drug Administration (FDA) an amended protocol for its Phase 2 clinical trial of lead candidate bryostatin-1...

Read More
Press Release

  Reaches Agreement with Iroquois Master Fund   NEWARK, N.J., August 5, 2016  — Neurotrope, Inc. (OTCBB:NTRP) (the “Company”), focused on developing drugs to treat neurological diseases including Alzheimer’s disease, today announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain...

Read More
Press Release

Therapeutics that target PKC Epsilon to Restore Lost Brain wiring show unique potential to treat both Genetic Mental Retardation (Fragile X) and Alzheimer’s Disease     NEWARK, N.J., June 13, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP): Dr. Daniel Alkon, Chief Scientific Officer of Neurotrope,  discussed “Modulation...

Read More
Press Release

  NEWARK, N.J., May 18, 2016 /PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), is pleased to announce that it has entered into a research collaboration with the International Rett Syndrome Foundation,...

Read More
Press Release

  Bryostatin, currently being tested  in a Phase 2b clinical trial in Alzheimer’s Dementia, causes regeneration of synaptic networks in both Alzheimer’s and Fragile X mouse models, neurodegenerative diseases at both ends of the age spectrum,  providing a potential major step toward a universal regenerative...

Read More
Press Release

    Interim Data Anticipated Q1 2017     Newark, NJ, February 11, 2016 – Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s...

Read More
Press Release

  Interim Data Anticipated Q1 2017   Newark, NJ, February 11, 2016 – Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.  ...

Read More
Press Release

  More than 150 Attendees from 30 Sites Nationwide   Newark, NJ, February 3, 2016 – Neurotrope, Inc. (NTRP) today announced that it has held an Investigators Meeting in conjunction with its recently initiated Phase 2b trial for lead compound, Bryostatin-1 for the treatment of...

Read More
Press Release

Existing Preferred Stock Investors Convert to Common Stock, Substantially Increasing Shareholders’ Equity.  Exercise of Strategically Designed Warrant Package Could Result in Over $100 million in Additional Funding   Newark, NJ, November 16, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that it has entered into definitive...

Read More
Press Release

  Newark, NJ, July 20, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) will be showcasing bryostatin as a potential treatment for Alzheimer’s Disease at the Alzheimer’s Association International Conference(R)(AAIC) being held July 18-23, 2015, in Washington,...

Read More
Press Release

Pre-clinical study funded by SOAR-NPC to examine effects of bryostatin in NPC mice.   Newark, NJ, June  24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary (“Neurotrope”), will conduct a preclinical study, in collaboration with a leading...

Read More
Press Release

  Studies to evaluate the effects of bryostatin-1 in a Fragile X Syndrome mouse model over a thirteen week period   Newark, NJ, April 16, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope BioScience, Inc., its wholly-owned operating subsidiary, has received a grant...

Read More
Press Release

  Newark, NJ, April 6, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the...

Read More
Press Release

  Study Meets Primary Endpoint of Safety and Tolerability     Newark, NJ, February 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced positive top-line results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer’s disease...

Read More
Press Release

  Study Meets Primary Endpoint of Safety and Tolerability   Newark, NJ, February 24, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced positive top-line results from its randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin-1 for the treatment of Alzheimer’s disease (AD)....

Read More
Press Release

  Newark, NJ, January 13, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced the formation of its Alzheimer’s Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, MD, ScD, CCF, Martin R. Farlow, MD, Sam Gandy, MD, PhD, Christina Sampaio, MD, PhD,...

Read More
Press Release

  Newark, NJ, January 6, 2015 — Neurotrope, Inc. (OTCQB: NTRP) today announced it is scheduled to present at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 – 14, 2015. Charles S. Ramat,...

Read More
Press Release

  Neurotrope’s Collaborator BRNI, Publishes Article in the Journal of Alzheimer’s Disease describing correlation of PKCe levels and degree of disease   Plantation, FL – August 18, 2014 – Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, “PKCe Deficits in...

Read More
Press Release

Plantation, FL – July 29, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer’s disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C...

Read More
Press Release

– Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 –   Plantation, FL – July 22, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the...

Read More
Press Release

Plantation, FL – July 18, 2014 – Neurotrope, Inc. (OTCQB: NTRP) today announced that on July 16, 2014, its Board of Directors appointed Co-Chairmen Charles S. Ramat and Paul Freiman as Co-Chief Executive Officers on an interim basis, effective immediately. Messrs. Ramat and Freiman replace...

Read More
Press Release

– Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 –   Plantation, FL. – July 15, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the...

Read More
Press Release

  – Neurotrope creates Office of the Chairman with Messrs. Ramat and Freiman as Co-Chairman of the Board. Dr. John Abeles to Remain on Board –   Plantation, FL. – June 19, 2014 – Neurotrope, Inc. (OTCQB: NTRP) has appointed Messrs. Charles S. Ramat and...

Read More
Press Release

  – Dr. Kongsamut specializes in age-related and neuroscience/CNS disorders –   Plantation, FL. – June 4, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today the appointment of Sam Kongsamut, Ph.D., as Executive Director, Pharmacology, effective immediately. In this role, Dr. Kongsamut will be responsible...

Read More
Press Release

– Preclinical data demonstrates reduction of Alzheimer’s brain deficits to lower toxic Aβ and restored synaptic loss –   Plantation, FL. – May 28, 2014 – Neurotrope, Inc. (OTCQB: NTRP) announced today the publication of positive human cell culture and mouse model data of Bryostatin...

Read More
Press Release

    Plantation, FL. – May 20, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has signed an agreement with Stanford University to study and, along with Dr. Paul Wender, investigate certain analogs of bryostatin, referred to as “bryologs”, as potential...

Read More
Press Release

Plantation, FL. – April , 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has applied for a provisional patent with the U.S. Patent & Trademark Office to protect its ability to use and commercialize its Bryostatin technology for the treatment of...

Read More
Press Release

Plantation, FL. – December 16, 2013 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that James Gottlieb has been appointed to the Company’s Board of Directors. Mr. Gottlieb has extensive senior level experience in a broad range of positions in Washington, D.C., in the...

Read More
Press Release

  Plantation, FL. – January 28, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that it has hired Dr. Richard Scheyer as Vice President and Chief Medical Officer, Mr. Ira Weisberg as Vice President, Commercial Operations and Mr. David Crockford as Vice President,...

Read More
Press Release

  Plantation, FL. – January 14, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that Dr. James New, the Company’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ Tenth Annual Equity Conference 11:00AM Eastern Time on Tuesday, January...

Read More
Press Release

  Plantation, FL. – January 6, 2014 – Neurotrope, Inc. (OTCQB: NTRP) (the “Company”) announced today that the Company will present at the Biotech Showcase 2014 conference 8:00AM Pacific Time on Monday, January 13, 2014 at the Parc 55 Wyndham Hotel, Union Square in San...

Read More
Press Release

Plantation, FL. – October 22, 2013 – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that Paul E. Freiman has been appointed to the Company’s Board of Directors. Mr. Freiman has extensive pharmaceutical and biotechnology industry operating experience as a board member and Chief Executive Officer...

Read More
Press Release

Plantation, FL. – October 15, 2013  – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that Dr. Larry D. Altstiel, M.D., Ph.D. has been appointed to the Company’s Scientific Advisory Board. Dr. Altstiel is an expert in several neurodegenerative disease states with respect to their potential...

Read More
Press Release

Plantation, FL. – October 9, 2013 – Neurotrope, Inc. (OTCQB:NTRP) (the “Company”) announced today that it completed a closing of the sale of 1,080,000 shares of its Series A convertible preferred stock in a private offering to accredited investors, at a price of $1.00 per...

Read More
Press Release

Plantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer. Mr. Weinstein had been the acting Chief...

Read More
Press Release

  Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering   Plantation, Fla. – August 29, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB: BLFLD), a Nevada corporation (the “Company”), announced today that it completed a reverse merger on August 23,...

Read More

EVENTS & PRESENTATIONS

Upcoming Events

There are currently no events to display.

Past Events

DatesEvent DetailsResources
March 12, 2018Cowen 38th Annual Healthcare Conference PresentationListen to webcast
January 29, 2018Noble Conference Corporate Presentation 2018Listen to webcast
January, 2018Noble Conference Alzheimer's PanelListen to webcast
January 7, 2018Sachs Annual Neuroscience BioPartnering & Investment Forum
July 17, 2017Alzheimer's Association International Conference 2017

CORPORATE GOVERNANCE

Our Board sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of our Board to serve as a prudent fiduciary for stockholders and to oversee the management of our business. To fulfill its responsibilities and to discharge its duty, our Board follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as our Board deems appropriate in our best interest or as required by applicable laws and regulations.

TitleDownload
Audit Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Committee Charter
Code of Conduct

FINANCIALS & FILINGS

Filing DateFormDescriptionView
March 31, 201810-QQuarter ended March 31, 2018
March 8, 2018SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
March 6, 201810-KAnnual report [Section 13 and 15(d), not S-K Item 405]
February 14, 2018SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
January 8, 20188-KCurrent report, items 7.01 and 9.01 
December 22, 2017S-8Securities to be offered to employees in employee benefit plans
December 22, 2017S-8Securities to be offered to employees in employee benefit plans
December 18, 20178-KCurrent report, items 1.01, 5.02, 5.07, and 9.01 
December 4, 2017DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
November 3, 201710-QQuarterly report [Sections 13 or 15(d)]
October 31, 2017DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
October 30, 2017DEF 14AOther definitive proxy statements
October 19, 20178-KCurrent report, item 8.01 
August 8, 201710-QQuarterly report [Sections 13 or 15(d)]
May 12, 201710-QQuarterly report [Sections 13 or 15(d)]
May 1, 20178-KCurrent report, items 8.01 and 9.01 
April 21, 2017EFFECTNotice of Effectiveness
April 19, 2017CORRESP[Cover]Correspondence
April 14, 20178-KCurrent report, items 5.02 and 9.01 
April 14, 2017CORRESP[Cover]Correspondence
April 14, 2017S-3/A[Amend] Registration statement under Securities Act of 1933
April 7, 2017EFFECTNotice of Effectiveness
April 7, 2017EFFECTNotice of Effectiveness
March 31, 2017POS AMPost-Effective amendments for registration statement
March 31, 2017POS AMPost-Effective amendments for registration statement
March 31, 2017S-3Registration statement under Securities Act of 1933
March 28, 2017CERTNAS[Paper]Certification by the Nasdaq Stock Market approving securities for listing
March 27, 20178-A12BRegistration of securities [Section 12(b)]
March 27, 20178-KCurrent report, items 8.01 and 9.01 
March 10, 201710-KAnnual report [Section 13 and 15(d), not S-K Item 405]
February 24, 20178-KCurrent report, items 5.03, 5.07, and 9.01 
February 22, 20178-KCurrent report, item 5.02 
February 14, 2017EFFECTNotice of Effectiveness
February 14, 2017424B3Prospectus [Rule 424(b)(3)]
February 14, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
February 13, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
February 13, 2017CORRESP[Cover]Correspondence
February 10, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
February 6, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
January 30, 2017S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
January 30, 2017CORRESP[Cover]Correspondence
January 30, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
January 24, 2017DEF 14AOther definitive proxy statements
January 17, 2017SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
January 12, 2017424B3Prospectus [Rule 424(b)(3)]
January 12, 2017PRE 14AOther preliminary proxy statements
January 12, 20178-KCurrent report, items 3.03, 5.03, and 9.01 
January 6, 2017424B3Prospectus [Rule 424(b)(3)]
January 6, 20178-KCurrent report, item 5.02 
January 3, 2017UPLOAD[Cover]SEC-generated letter
December 19, 2016S-1General form for registration of securities under the Securities Act of 1933
December 1, 2016DNotice of Exempt Offering of Securities, item 06b 
November 23, 20168-KCurrent report, items 5.02 and 9.01 
November 22, 20168-KCurrent report, items 1.01, 3.02, and 9.01 
November 18, 20168-KCurrent report, item 5.02 
November 18, 2016424B3Prospectus [Rule 424(b)(3)]
November 18, 20168-KCurrent report, items 1.01, 3.02, 3.03, 5.03, 8.01, and 9.01 
November 14, 201610-QQuarterly report [Sections 13 or 15(d)]
November 14, 2016424B3Prospectus [Rule 424(b)(3)]
November 2, 2016EFFECTNotice of Effectiveness
October 21, 2016POS AMPost-Effective amendments for registration statement
September 29, 2016424B3Prospectus [Rule 424(b)(3)]
September 28, 20168-KCurrent report, item 5.02 
September 2, 20168-KCurrent report, item 5.02 
August 18, 2016424B3Prospectus [Rule 424(b)(3)]
August 17, 20168-KCurrent report, item 5.02 
August 16, 2016424B3Prospectus [Rule 424(b)(3)]
August 15, 201610-QQuarterly report [Sections 13 or 15(d)]
August 12, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
August 9, 2016SC 13D/A[Amend] General statement of acquisition of beneficial ownership
August 8, 2016424B3Prospectus [Rule 424(b)(3)]
August 5, 20168-KCurrent report, items 1.01, 5.02, and 9.01 
July 25, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
July 15, 2016SC 13DGeneral statement of acquisition of beneficial ownership
July 14, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
July 7, 2016PREC14APreliminary proxy statements, contested solicitations
June 1, 2016424B3Prospectus [Rule 424(b)(3)]
May 13, 201610-QQuarterly report [Sections 13 or 15(d)]
April 15, 20168-KCurrent report, items 5.03, 5.07, and 9.01 
April 12, 2016424B3Prospectus [Rule 424(b)(3)]
March 18, 2016DEF 14AOther definitive proxy statements
March 8, 2016PRE 14AOther preliminary proxy statements
March 7, 201610-KAnnual report [Section 13 and 15(d), not S-K Item 405]
February 23, 20168-KCurrent report, items 7.01 and 9.01 
February 18, 20168-KCurrent report, item 5.02 
February 16, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
February 10, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
February 8, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
February 8, 2016SC 13GStatement of acquisition of beneficial ownership by individuals
January 20, 2016424B3Prospectus [Rule 424(b)(3)]
January 19, 2016EFFECTNotice of Effectiveness
January 14, 2016CORRESP[Cover]Correspondence
January 14, 2016S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
December 22, 2015CT ORDERConfidential treatment order
December 22, 2015UPLOAD[Cover]SEC-generated letter
December 11, 2015S-1General form for registration of securities under the Securities Act of 1933
December 7, 2015424B3Prospectus [Rule 424(b)(3)]
December 4, 20158-KCurrent report, items 1.01, 3.02, 5.01, and 9.01 
November 24, 2015DNotice of Exempt Offering of Securities, item 06b 
November 20, 2015424B3Prospectus [Rule 424(b)(3)]
November 19, 20158-KCurrent report, items 1.01, 3.02, 3.03, 5.01, 5.03, and 9.01